Skip to main content
Immunotech Biopharm Ltd logo

Immunotech Biopharm Ltd — Investor Relations & Filings

Ticker · 6978 ISIN · KYG4721A1004 HKEX Manufacturing
Open in API
Filings indexed 256 across all filing types
Latest filing 2024-11-04 Regulatory Filings
Country HK Hong Kong
Listing HKEX 6978

About Immunotech Biopharm Ltd

http://www.eaal.net

Immunotech Biopharm Ltd is a biopharmaceutical company specializing in the research, development, manufacturing, and commercialization of cellular immunotherapy products. The company focuses primarily on T cell immunotherapy, applying principles of immunology, cell biology, and genetics combined with advanced technology to develop treatments for malignant tumors and other major diseases. Founded in 2006, it is recognized as a pioneer in the domestic development of cellular immunotherapy products. It maintains a commitment to building systematic R&D platforms and GMP-compliant manufacturing facilities for individualized cell products.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2024
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 31 October 2024. It details movements in authorised/registered share capital, issued shares, share options, convertibles, and confirms compliance with listing rules. It is a regulatory submission to the Hong Kong Exchanges and Clearing Limited, focusing on share capital and securities movements rather than financial performance or management commentary. It does not contain financial statements or earnings data, nor is it an announcement of a report publication. The document fits the category of a regulatory filing related to share capital and securities movements under exchange rules, which aligns best with the 'Regulatory Filings (RNS)' category as a general regulatory announcement and compliance document that does not fit other specific categories.
2024-11-04 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2024
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' and covers movements in authorized share capital, issued shares, share options, convertibles, and confirmations related to compliance with listing rules. It is a regulatory submission to the Hong Kong Exchanges and Clearing Limited, detailing share capital and share movements for the month ended 30 September 2024. The document is about share capital changes and confirmations of compliance, not a financial report, earnings release, or management discussion. It fits the category of Share Issue/Capital Change announcements, which cover new share issues, stock splits, or other capital changes. The document length is over 10,000 characters and contains detailed data on share capital movements, consistent with a SHA filing rather than a brief announcement or a report publication notice.
2024-10-07 English
2024 INTERIM REPORT
Interim / Quarterly Report Classification · 100% confidence The document is titled '2024 Interim Report' and contains detailed financial and operational data highlights, corporate information, management discussion and analysis, and condensed consolidated financial statements. It covers a six-month period ended 30 June 2024, which is typical for an interim or quarterly report. The presence of unaudited financial data, management discussion, and condensed financial statements confirms it is a comprehensive financial report for a period shorter than a full fiscal year. Therefore, this document fits the definition of an Interim / Quarterly Report (IR).
2024-09-19 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2024
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 31 August 2024. It details movements in authorised/registered share capital, issued shares, share options, convertibles, and confirms compliance with listing rules. It is a regulatory submission to the Hong Kong Exchanges and Clearing Limited, reporting share capital and share movements for the month. It does not contain financial statements, earnings data, or management discussion. It is a regulatory filing reporting share capital movements and confirmations under listing rules, typical of a Regulatory Filings (RNS) document rather than a financial report or announcement of a report. The document length is over 10,000 characters and contains detailed data, but it is not a financial report or announcement of a report publication. Therefore, the best classification is Regulatory Filings (RNS).
2024-09-04 English
ANNOUNCEMENT OF THE INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2024
Interim / Quarterly Report Classification · 100% confidence The document is titled 'ANNOUNCEMENT OF THE INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2024' and contains detailed financial data for the six-month period ending June 30, 2024, including income, expenses, loss before tax, and balance sheet items. It also includes a Management Discussion and Analysis section describing business operations, R&D pipeline, and clinical trial progress. The document is unaudited and covers a half-year period, which aligns with an Interim / Quarterly Report. The length is substantial (15,000 characters), and it contains substantive financial data and analysis, not just an announcement or summary. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2024-08-23 English
DATE OF BOARD MEETING
Report Publication Announcement Classification · 95% confidence The document is an announcement from Immunotech Biopharm Ltd regarding the scheduling of a board meeting to consider and approve the interim results for the six months ended 30 June 2024. It does not contain the interim financial report itself but only informs about the upcoming board meeting and the intention to publish the interim results. The document length is short (1431 characters) and it is clearly an announcement rather than the report itself. According to the 'Menu vs Meal' rule, this is a Report Publication Announcement (RPA) type document, as it announces the timing of the report's approval and publication but does not include the report or substantive financial data.
2024-08-13 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.